Oncology · GlioblastomaTrial Updateclinicalmid-term

BMS-986504 Trial Initiated for Recurrent Glioblastoma Patients with MTAP Loss

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Bristol Myers Squibb17 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 6:32:23 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the BMS-986504 trial for recurrent glioblastoma patients with MTAP loss represents a significant development in oncology, particularly in a challenging therapeutic area. Monitoring the trial's progress will be crucial for understanding its potential impact on treatment options and competitive positioning in glioblastoma therapies. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read.

Strategic Assessment

Monitoring the trial's outcomes could inform strategic decisions regarding investment in glioblastoma treatments and potential partnerships. The strongest clinical anchor is Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (ClinicalTrials.gov), entity match (recurrent glioblastoma); patient population match (recurrent). In Oncology · Glioblastoma, 5 regulatory and 5 competitive items passed relevance filtering for BMS-986504.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck). Secondary pressure from Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Regulatory pathway relevance (indication). Relevant agencies in corpus: FDA, MHRA. The trial's results may influence future regulatory submissions and approvals, particularly if the drug demonstrates efficacy in a previously underserved patient population.

Key Risks

Elevated medium regulatory exposure for BMS-986504 could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful outcomes from this trial could enhance BMS-986504's market positioning, potentially leading to increased revenue opportunities in a high-need area of oncology.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Lead sponsor: NewLink Genetics Corporation. The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.
How we engage and involve patients and the public in our regulatory decision-making.

What Would Change This Assessment

This becomes more urgent if Key milestones include results from the Phase 0 component and subsequent enrollment into Phase 1 based on pharmacokinetic responses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
ClinicalTrials.govhigh relevance
Entity match (recurrent glioblastoma); Patient population match (recurrent)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Patient population match (recurrent)
FDA document
View source
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ClinicalTrials.govhigh relevance
Patient population match (recurrent)
FDA document
View source
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer
Humanexa Signalshigh relevance
Patient population match (recurrent)
Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.
PubMedhigh relevance
Entity match (recurrent glioblastoma); Patient population match (recurrent)
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

BMS-986504
MRTX1719
recurrent glioblastoma

Commercial impact

medium

Successful outcomes from this trial could enhance BMS-986504's market positioning, potentially leading to increased revenue opportunities in a high-need area of oncology.

Regulatory impact

medium

The trial's results may influence future regulatory submissions and approvals, particularly if the drug demonstrates efficacy in a previously underserved patient population.

What to watch

Key milestones include results from the Phase 0 component and subsequent enrollment into Phase 1 based on pharmacokinetic responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.